# Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

> **NCT06846346** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 88 (estimated)

## Conditions studied

- Metastatic Esophageal Adenocarcinoma
- Advanced Esophageal Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** FOLFOX regimen
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06846346
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-09
- **Final completion:** 2028-09
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846346, "Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06846346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*